Eli Lilly is betting on a pediatric expansion to give it’s IL-23p19 inhibitor Omvoh an edge in the fiercely competitive ...

Amid a steady advance of kidney-focused label expansions, Novartis’ Fabhalta is slowing its roll in a key potential autoimmune niche.  | Amid a steady advance of kidney-focused label expansions, ...

Amid tensions over government healthcare cost-cutting policies, Roche has slammed the brakes on new investments in Germany, joining an expanding group of drugmakers pulling back from the European ...

EyePoint shares plummeted more than 84% Monday morning after the company announced that its phase 3 Lucia trial—its final holdout in wet age-related macular degeneration (wet AMD) following a previ | ...

Central to the new report (PDF) are the JEC Democrats' findings that Trump increased his stock holdings in the pharmaceutical ...

Hot off a pair of key FDA green lights this summer, rare disease specialist Ultragenyx has wasted little time cashing in a ...

In the fiercely competitive inflammatory bowel disease (IBD) market, Eli Lilly is making the case for its antibody Omvoh as a ...

Novo has long sold a separate version of oral semaglutide for diabetes under the brand name Rybelsus, which the medicine ...

Following a bumpy regulatory road that involved a refusal-to-file, ImmunityBio has won FDA approval to expand Anktiva into ...

Expanding its presence in dermatology, Cetaphil maker Galderma has agreed to acquire professional skincare shop Zo Skin ...

With a yearslong patent dispute between the two drugmakers finally put to bed—complete with a hefty settlement payout—United ...

As the momentum continues to pick up at NorthStar Medical Technologies, the radioisotope producer is strengthening ties in ...